In the spotlight

ISTH and EAHAD Educational Partnership on Gene Therapy

The International Society on Thrombosis and Haemostasis (ISTH) and the European Association for Haemophilia and Allied Disorders (EAHAD) have announced an educational partnership to collaborate on components of the ISTH Gene Therapy in Hemophilia Education Initiative.
Together, the ISTH and EAHAD will work with The France Foundation (TFF) to develop and distribute tailored educational materials for the primarily European hemophilia practice community, including: a survey for allied health professionals, train-the-trainer workshops, podcast episodes, an EAHAD 2021 conference briefing and other learning sessions.


These resources will be available through the ISTH Gene Therapy in Hemophilia Education Initiative website along with an extensive archive of other educational materials keeping healthcare professionals up to date on this developing treatment option. EAHAD will also promote the content on a dedicated section of its website.
“The ISTH Gene Therapy in Hemophilia Education Initiative seeks to continuously provide the latest updates on the rapidly evolving treatment options for hemophilia, and partnerships like this one between the ISTH and EAHAD are essential to developing relevant content and distributing the information to the widest audience,” said Flora Peyvandi, M.D., Ph.D., Co-Chair of the ISTH Gene Therapy for Hemophilia Steering Committee and current President of EAHAD. “Scientists and physicians around the world are being challenged to keep current with the latest scientific developments and clinical advancements, and these educational programs are critical to ensure they are ready to deliver the best patient care when treatments like gene therapy become available.”
To learn more and view educational resources visit

One of the priorities of EAHAD going forward is the development of activities and structures to support the development of gene therapy. Our Gene Therapy Working Group aims to provide critical information to physicians and patients about gene therapy in terms of practicability and safety. We look forward to sharing more information on our Working Group activities soon.
You can read the press release in full here